IVME In Veritas Medical Diagnostics Inc (CE)

In Veritas Medical Diagnostics (OTCBB:IVME), a novel medical device company, today announced the presentation for the National Investment Banking Association (NIBA) Conference held this May in San Diego is available to the public at the Company's website, http://www.ivmd.com. The presentation reviews business and financial developments, trends relating to IVMD's unique, patented technology and the global, rapid diagnostic testing products the company is developing. John Fuller, President and CEO, and Brian Cameron, Chief Operating Officer, presented to investors at the NIBA conference the rich product pipeline and market opportunities coming out of In Veritas over the next four years from the growing patent portfolio held exclusively by In Veritas. In Veritas develops and manufactures non- or low invasive point of care medical devices based on Hall Effect technology. Its first device to market, a prothrombin time monitor developed for people at risk of cardiovascular disease, is scheduled for initial launch in the UK during the third quarter followed by a full scale launch in the U.S. for the first quarter, 2006. In Veritas is also expecting to launch its fetal heart monitor and prediction of labor onset (POLO) device during 2006 and its ImmunoAssay device in 2007. Mr. Fuller commented, "We are in the process of implementing the commercialization strategy for our medical devices; we have a strong pipeline and are rapidly executing the development, manufacturing and launching of our medical devices. In addition, we are interested in keeping the investment community abreast of our developments and strategy while we build shareholder value." About In Veritas Medical Diagnostics, Inc. In Veritas Medical Diagnostics, Inc. consists of two wholly-owned subsidiaries based in the UK, IVMD (UK) Ltd. and Jopejo Ltd. IVMD (UK) is in the final stage of its first groundbreaking medical device for the multi-billion dollar cardio-vascular market. Other medical conditions being addressed by IVMD's patented technology include the diabetes market and other areas where imaging is essential. Although the Hall Effect, the basic phenomena behind much of IVMD's technology, has been known since 1875, it is only through recent developments in semi-conductor technology and computing power that scientists have been able to apply it to the measurement of the magnetic properties of bone and tissue -- thereby enabling the Hall Effect to be considered in medical uses. The Hall Effect is a principle of physics discovered by E.H. Hall that is the measurable transverse voltage that occurs when an electric current flows through a conductor in a magnetic field. IVMD has a substantial portfolio of patents and patent applications relating to its technology. Jopejo Ltd. is also in the late stages of developing new and technically superior monitoring devices that utilize signal processing for the late-term pregnancy market. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "believe," "expects," "projects," "forecasts," "intends," "will," "anticipated," "could," or "may," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act and are subject to the safe harbor created by the act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.